Noveris Health Sciences Inc. (CSE:NVRS)
Canada · Delayed Price · Currency is CAD 0.4150
+0.0700 (20.29%)
At close: Aug 10, 2026
Noveris Health Sciences Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| - | - | - | - | - | 0.01 | |
Revenue Growth | - | - | - | - | - | 186.32% |
Gross Profit | - | - | - | - | - | 0.01 |
Selling, General & Admin | 0.49 | 0.55 | 2.51 | 8.3 | 12.2 | 15.05 |
Research & Development | -0.04 | -0.04 | - | 1.08 | 3.51 | 3.96 |
Operating Expenses | 0.45 | 0.51 | 2.51 | 9.39 | 15.84 | 22.34 |
Operating Income | -0.45 | -0.51 | -2.51 | -9.39 | -15.84 | -22.33 |
Interest Expense | -0.09 | -0.22 | -1.45 | -1.3 | -0.91 | -0.21 |
Currency Exchange Gain (Loss) | 0.23 | 0.22 | -0.32 | -0 | -0.18 | -0.36 |
Other Non Operating Income (Expenses) | -1.77 | -0.45 | 0.1 | -3.88 | 0.54 | -0.31 |
EBT Excluding Unusual Items | -2.08 | -0.96 | -4.18 | -14.58 | -16.39 | -23.2 |
Gain (Loss) on Sale of Investments | - | - | - | -5.14 | 0.96 | - |
Gain (Loss) on Sale of Assets | - | - | 0.05 | - | -0.32 | - |
Other Unusual Items | 3.68 | 3.88 | 0.95 | -1.23 | - | -0.38 |
Pretax Income | 1.6 | 2.92 | -3.17 | -20.95 | -15.75 | -23.58 |
Earnings From Continuing Operations | 1.6 | 2.92 | -3.17 | -20.95 | -15.75 | -23.58 |
Earnings From Discontinued Operations | - | - | - | - | 6.5 | -5.31 |
Net Income | 1.6 | 2.92 | -3.17 | -20.95 | -9.25 | -28.9 |
Net Income to Common | 1.6 | 2.92 | -3.17 | -20.95 | -9.25 | -28.9 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 5 | 1 | 1 | 1 | 0 | 0 |
Shares Outstanding (Diluted) | 5 | 1 | 1 | 1 | 0 | 0 |
Shares Change | 297.18% | 3.57% | 94.24% | 254.98% | 84.71% | 105.85% |
EPS (Basic) | 0.33 | 2.37 | -2.66 | -34.12 | -53.48 | -308.62 |
EPS (Diluted) | 0.33 | 2.37 | -2.66 | -34.12 | -53.48 | -308.62 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -0.28 | 0.01 | -0.04 | -4.22 | -8.43 | -24.34 |
Free Cash Flow Per Share | -0.06 | 0.01 | -0.03 | -6.87 | -48.73 | -259.99 |
Gross Margin | - | - | - | - | - | 100.00% |
Operating Margin | - | - | - | - | - | -298069.65% |
Profit Margin | - | - | - | - | - | -385658.60% |
Free Cash Flow Margin | - | - | - | - | - | -324889.79% |
EBITDA | - | - | -2.5 | -9.38 | -15.71 | -22.19 |
D&A For EBITDA | - | - | 0.01 | 0.01 | 0.13 | 0.15 |
EBIT | -0.45 | -0.51 | -2.51 | -9.39 | -15.84 | -22.33 |